Improved circular rna for expressing therapeutic proteins
AssigneeCureVac AG
InventorDipankar BHANDARI
Life of this patent
Estimating the term…
Loading patent…
AssigneeCureVac AG
InventorDipankar BHANDARI
Estimating the term…
The present invention is inter alia directed to improved circular RNA constructs comprising (i) at least one translation initiation sequence, (ii) at least one coding sequence (cds), (iii) at least one UTR sequence, and (iv) at least one poly(A) sequence. Further provided is linear precursor RNA for making such an improved circular RNA. The invention also relates to improved methods for preparing circular RNA and to improved methods of purifying circular RNA. Moreover, the invention relates to pharmaceutical compositions, vaccines, combinations, and kit or kit of parts comprising the circular RNA of the invention. Also provided are methods of treating or preventing disorders or diseases, and first, second, and further medical uses.
A circular RNA comprising the following sequence elements in the following order
The circular RNA of any one of the preceding claims, wherein the at least one UTR comprises or consists of a nucleic acid sequence derived from a 3′-UTR of a gene selected from PSMB3, ALB7, alpha-globin, CASP1, COX6B1, GNAS, NDUFA1, AES-12S and RPS9, or from a homolog, a fragment or a variant of any one of these genes, or wherein the at least one UTR comprises or consists of a nucleic acid sequence derived from a 5′-UTR of a gene selected from HSD17B4, RPL32, ASAH1, ATP5A1, MP68, NDUFA4, NOSIP, RPL31, SLC7A3, TUBB4B, HBA1, HBA2 and UBQLN2, or from a homolog, a fragment or a variant of any one of these genes.
The circular RNA of any one of the preceding claims, wherein the at least one UTR has a length of less than about 200 nucleotides or a length between 50 and 200 nucleotides.
The circular RNA of any one of the preceding claims, wherein the at least one UTR comprises or consists of an RNA sequence being identical or at least 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs:
The circular RNA of any one of the preceding claims, wherein the at least one UTR is a downstream UTR located between the coding sequence and the at least one Poly(A) sequence.
The circular RNA of any one of the preceding claims, additionally comprising at least one upstream UTR sequence, preferably derived from a 5′-UTR of a gene selected from HSD17B4, RPL32, ASAH1, ATP5A1, MP68, NDUFA4, NOSIP, RPL31, SLC7A3, TUBB4B, HBA1, HBA2 and UBQLN2.
The circular RNA of any one of the preceding claims, wherein the at least one coding sequence is a codon modified coding sequence, wherein the amino acid sequence encoded by the at least one codon modified coding sequence is preferably not being modified compared to the amino acid sequence encoded by the corresponding wild type or reference coding sequence.
The circular RNA of any one of the preceding claims, wherein the at least one coding sequence has a G/C content of at least about 55%, 60%, or 65%.
The circular RNA of any one of the preceding claims, wherein coding sequence encodes at least one peptide or protein suitable for use in treatment or prevention of a disease, disorder or condition.
The circular RNA of any one of the preceding claims, wherein the at least one translation initiation sequence is a cap-independent translation initiation element.
The circular RNA of any one of the preceding claims, wherein the at least one translation initiation sequence is selected from an internal ribosomal entry site (IRES), an aptamer, and a CITE element.
The circular RNA of any one of the preceding claims, wherein the translation initiation sequence, preferably the IRES, is located upstream of the start codon of the at least one coding sequence.
The circular RNA of any one of the preceding claims, wherein the RNA sequence located upstream of the translation initiation sequence (in opposing direction of translation) is a unstructured sequence element, e.g. an AC rich sequence.
The circular RNA of any one of the preceding claims, wherein the circular RNA additionally comprises at least one Kozak sequence, preferably selected or derived from any one of SEQ ID NOs:169-176 (GCCGCCACCAUGG, GCCGCCACC, GCCACC, ACC), or a fragment or a variant of any of these, more preferably selected or derived from GCCACC, or a fragment or a variant.
The circular RNA of any one of the preceding claims, wherein the at least one Kozak sequence is located directly upstream of the start codon of the at least one coding sequence.
The circular RNA of any one of the preceding claims, wherein the at least one Kozak sequence is located downstream of the at least one IRES sequence.
The circular RNA of any one of the preceding claims, additionally comprising at least one poly(C) sequence and/or at least one histone-stem loop sequence and/or at least one miRNA binding site.
The circular RNA of any one of the preceding claims, wherein the circular RNA consists of ribonucleotides linked via phosphodiester-bonds.
The circular RNA of any one of the preceding claims, wherein the circular RNA comprises at least one splice-junction element.
The circular RNA of any one of the preceding claims, wherein the circular RNA has a length of at least 500 ribonucleotides, preferably wherein the circular RNA has a length ranging from about 500 ribonucleotides to about 5000 ribonucleotides.
The circular RNA of any one of the preceding claims, wherein the circular RNA has been circularized via self-splicing from a linear single stranded precursor RNA.
The circular RNA of any one of the preceding claims, wherein the circular RNA has an RNA integrity of at least about 50%, preferably of at least about 60%, more preferably of at least about 70%, most preferably of at least about 80%.
The circular RNA of any one of the preceding claims, wherein upon administration of the circular RNA to a cell or subject, the circular RNA has reduced immunostimulatory properties compared to a corresponding reference RNA.
The circular RNA of any one of the preceding claims, wherein upon administration of the circular RNA to a cell or subject, the circular RNA has a prolonged protein expression compared to a corresponding reference RNA.
The circular RNA of any one of the preceding claims, wherein upon administration of the circular RNA to a cell or subject, the circular RNA has a prolonged protein expression in cells that are characterized by a reduced/lowered eIF4F expression compared to a corresponding reference RNA.
The pharmaceutical composition of claims 69 to 79, wherein the lipid-based carriers comprise
A combination comprising the following components
A method of purifying a circular RNA from a composition comprising linear precursor RNA and circular RNA comprising a step of
A method for preparing circular RNA comprising the steps of
Dependencies are inferred from the claim text.